In vitro HIV-specific CTL activity from HIV-seropositive individuals is augmented by interleukin-12 (IL-12)

被引:7
作者
Young, JM [1 ]
Ffrench, RA
Clarkson, JD
Stewart, GJ
Liang, T
Tideman, RL
Packham, D
Fulcher, DA
Benson, EM
机构
[1] Westmead Hosp, ICPMR, Dept Immunopathol, Westmead, NSW 2145, Australia
[2] Westmead Hosp, Dept Immunol, Westmead, NSW 2145, Australia
[3] Sydney Childrens Hosp, Paediat Res Labs, Randwick, NSW, Australia
[4] Nepean Hosp, Nepean Sexual Hlth Clin, Penrith, NSW 2750, Australia
[5] Sydney Hosp, Acad Unit Sexual Hlth Med, Sydney, NSW, Australia
[6] Westmead Hosp, Dept Infect Dis, Westmead, NSW 2145, Australia
关键词
D O I
10.1089/088922201750063151
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IL-12 production is reduced in HIV infection, and recombinant human IL-12 (rhIL-12) augments in vitro HIV-specific proliferative responses in PBMC from HIV-seropositive individuals. To determine whether rhIL-12 could also augment HIV-specific CTL responses we studied 41 HIV-seropositive individuals. Recombinant hIL-12 increased the detectable in vitro HIV-specific CD8 CTL activity of PBMC taken from HIV-seropositive individuals with CD4 counts >500 cells/mul and from some individuals with lower CD4 counts. IL-12 increased cell recovery in cultures of PBMC from HIV-seropositive individuals with CD4 counts >500 cells/mul and also increased the precursor CTL frequency. However, the increase in HIV-specific CTL activity was not due to IL-2 or IFN-gamma production or an increase in the number of cells with surface markers characteristic of CTL effector cells. This study demonstrates that rhIL-12 augments in vitro HIV-specific CTL activity and provides evidence to justify further investigation within clinical trials of this cytokine in HIV infection.
引用
收藏
页码:233 / 242
页数:10
相关论文
共 47 条